What’s Going On With Evolve Transition Stock Today?

Evolve Transition Infrastructure LP (AMEX: SNMP) common units surged Monday. The company last week announced the removal by NYSE American of the trading suspension on the stock. 

Evolve Transition Infrastructure LP (AMEX:SNMP) common units surged Monday. The company last week announced the removal by NYSE American of the trading suspension on the stock. 

What To Know: The company announced last Wednesday, according to a letter from NYSE American, that the continued listing deficiency with respect to low selling price was resolved. The company’s delisting determination would be withdrawn, the trading suspension on the Partnership’s common units would be lifted and the common units would commence trading on the NYSE American on July 31 under the symbol “SNMP.”

However, delisting proceedings may again be enacted if the Partnership is not in compliance with the continued listing standards by June 6 of next year.

On Monday, the common units soared over 700% after they commenced trading. However, several times throughout the day, they were halted and then resumed trading.

Also of note, the stock recently initiated a 1-for-30 reverse split which gave one common unit for every thirty common units they owned at the close of trading on July 17.

Related Link: Eagle Materials Capitalizes On Strong Cement Pricing Despite Wallboard Slowdown: Analyst

SNMP Price Action: Shares of SNMP were up 765.4% at $4.50 at the time of publication, according to Benzinga Pro.

Image by David Mark from Pixabay

 

 

Total
0
Shares
Related Posts
Read More

AffaMed Therapeutics Announced Top-Line Results From Real-World Study In China Evaluating The Safety And Efficacy Of DEXTENZA In Patients After Cataract Surgery; NOTE: AffaMed Therapeutics Has A Licensing Agreement With Ocular Therapeutix, Inc.

AffaMed Therapeutics ("AffaMed"), a global biotechnology company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products that address critical unmet medical needs in

OCUL

Read More

Reported Sunday, BioNTech Three-Year Phase 1 Follow-Up Data For mRNA-based Individualized Immunotherapy Candidate Shows Persistence Of Immune Response And Delayed Tumor Recurrence In Some Patients With Resected Pancreatic Cancer

Three-year follow-up data of an investigator-initiated Phase 1 trial of the individualized mRNA cancer vaccine candidate autogene cevumeran (BNT122, RO7198457) continue to show polyspecific T cell responses up to

BNTX